SG Americas Securities’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.43M Sell
60,180
-43,289
-42% -$1.2M ﹤0.01% 1549
2025
Q4
$2.87M Buy
103,469
+60,249
+139% +$1.54M ﹤0.01% 1345
2025
Q3
$1.05M Buy
43,220
+36,004
+499% +$716K ﹤0.01% 1414
2025
Q2
$123K Sell
7,216
-8,822
-55% -$154K ﹤0.01% 2546
2025
Q1
$313K Buy
16,038
+3,920
+32% +$103K ﹤0.01% 2177
2024
Q4
$301K Buy
12,118
+1,971
+19% +$50.3K ﹤0.01% 1792
2024
Q3
$249K Sell
10,147
-8,995
-47% -$232K ﹤0.01% 2306
2024
Q2
$448K Buy
19,142
+13,018
+213% +$320K ﹤0.01% 1729
2024
Q1
$202K Sell
6,124
-8,720
-59% -$272K ﹤0.01% 1968
2023
Q4
$404K Sell
14,844
-254
-2% -$6.31K ﹤0.01% 1614
2023
Q3
$363K Buy
+15,098
New +$405K ﹤0.01% 1969
2023
Q2
Sell
-16,277
Closed -$498K 2329
2023
Q1
$498K Buy
16,277
+12,090
+289% +$477K 0.01% 1723
2022
Q4
$164K Sell
4,187
-3,578
-46% -$160K ﹤0.01% 2348
2022
Q3
$370K Sell
7,765
-20,418
-72% -$1.16M ﹤0.01% 1810
2022
Q2
$1.09M Buy
28,183
+22,566
+402% +$897K 0.01% 1230
2022
Q1
$322K Sell
5,617
-8,985
-62% -$589K ﹤0.01% 2154
2021
Q4
$1.16M Sell
14,602
-6,065
-29% -$519K 0.01% 1535
2021
Q3
$1.8M Buy
20,667
+8,440
+69% +$848K 0.01% 1372
2021
Q2
$1.57M Buy
12,227
+1,281
+12% +$102K 0.01% 1273
2021
Q1
$876K Buy
+10,946
New +$1.04M ﹤0.01% 1641
2020
Q3
Sell
-6,866
Closed -$192K 2734
2020
Q2
$192K Buy
+6,866
New +$148K ﹤0.01% 2889

Other funds holding BEAM

SG Americas Securities's BEAM Position: Q1 2026 in Review

SG Americas Securities reduced its Beam Therapeutics (BEAM) stake by 42% in Q1 2026, selling an estimated $1.2M and leaving 60,180 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1549.

SG Americas Securities first reported a position in BEAM in Q2 2020 and has held it in 21 quarters since. The position peaked at $2.87M in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • SG Americas Securities held 60,180 shares of Beam Therapeutics worth $1.43M as of Q1 2026.
  • SG Americas Securities sold 43,289 Beam Therapeutics shares in Q1 2026, an estimated $1.2M.
  • Beam Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1549 holding.
  • SG Americas Securities first reported a position in Beam Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • SG Americas Securities's Beam Therapeutics position peaked at $2.87M in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.